-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $20

Benzinga·10/07/2026 19:13:05
Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $40 to $20.